Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer

被引：23

作者：

Han, Xin ^{[1
,2
]}

Zhao, Lijie ^{[1
,2
]}

Xiang, Weiguo ^{[1
,2
]}

Miao, Bukeyan ^{[1
,2
]}

Qin, Chong ^{[1
,2
]}

Wang, Mi ^{[1
,2
]}

Xu, Tianfeng ^{[1
,2
]}

McEachern, Donna ^{[1
,2
]}

Lu, Jianfeng ^{[1
,2
]}

Wang, Yu ^{[1
,2
]}

Metwally, Hoda ^{[1
,2
]}

Yang, Chao-Yie ^{[1
,2
]}

Kirchhoff, Paul D. D. ^{[1
,2
]}

Wang, Lu ^{[5
]}

Matvekas, Aleksas ^{[5
]}

Takyi-Williams, John ^{[5
]}

Wen, Bo ^{[5
]}

Sun, Duxin ^{[5
]}

Ator, Mark ^{[6
]}

Mckean, Robert ^{[6
]}

Wang, Shaomeng ^{[1
,2
,3
,4
]}

机构：

[1] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA

[3] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA

[4] Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA

[5] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA

[6] Oncopia Therapeut Inc, Malvern, PA 19355 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 66卷 / 13期

关键词：

PROTEIN-DEGRADATION; UBIQUITINATION; MOLECULES;

D O I：

10.1021/acs.jmedchem.3c00405

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We report the discovery of ARD-2051as a potent and orally efficaciousandrogen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051achieves DC50 values of 0.6 nM and D (max) >90% in inducing AR protein degradation in both theLNCaPand VCaP prostate cancer cell lines, potently and effectively suppressesAR-regulated genes, and inhibits cancer cell growth. ARD-2051 achievesa good oral bioavailability and pharmacokinetic profile in mouse,rat, and dog. A single oral dose of ARD-2051 strongly reduces AR proteinand suppresses AR-regulated gene expression in the VCaP xenografttumor tissue in mice. Oral administration of ARD-2051 effectivelyinhibits VCaP tumor growth and causes no signs of toxicity in mice.ARD-2051 is a promising AR degrader for advanced preclinical developmentfor the treatment of AR+ human cancers.

引用

页码：8822 / 8843

页数：22

共 50 条

[21] Discovery of the First Potent, Selective, and In Vivo Efficacious Polo-like Kinase 4 Proteolysis Targeting Chimera Degrader for the Treatment of TRIM37-Amplified Breast Cancer
Sun, Yin
Xue, Yanli
Sun, Pengkun
Mu, Shuyi
Liu, Hongbing
Sun, Yu
Wang, Lin
Wang, Jingkai
Wu, Tianxiao
Yin, Wenbo
Qin, Qiaohua
Sun, Yixiang
Liu, Nian
Wang, Hanxun
Yang, Huali
Zhao, Dongmei
Cheng, Maosheng
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (12) : 8200 - 8221
[22] Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy
Zhang, Dize
Ma, Bohan
Liu, Donghua
Wu, Wei
Zhou, Tianyang
Gao, Yibo
Yang, Cunli
Jian, Yanlin
Fan, Yizeng
Qian, Yuchen
Ma, Jian
Gao, Yang
Chen, Yule
Xu, Shan
Li, Lei
EBIOMEDICINE, 2024, 105
[23] Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
Qin, Chong
Hu, Yang
Zhou, Bing
Fernandez-Salas, Ester
Yang, Chao-Yie
Liu, Liu
McEachern, Donna
Przybranowski, Sally
Wang, Mi
Stuckey, Jeanne
Meagher, Jennifer
Bai, Longchuan
Chen, Zhuo
Lin, Mei
Yang, Jiuling
Ziazadeh, Danya N.
Xu, Fuming
Hu, Jiantao
Xiang, Weiguo
Huang, Liyue
Li, Siwei
Wen, Bo
Sun, Duxin
Wang, Shaomeng
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (15) : 6685 - 6704
[24] ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study
Petrylak, Daniel P.
McKean, Meredith
Lang, Joshua Michael
Gao, Xin
Dreicer, Robert
Geynisman, Daniel M.
Stewart, Tyler F.
Gandhi, Mitul
Appleman, Leonard Joseph
Dorff, Tanya B.
Chatta, Gurkamal S.
Tutrone, Ronald
De la Cerda, Jose
Berghorn, Elmer
Gong, Jiachang
Yu, Tinghui
Dominy, Erin
Chan, Edward
Shore, Neal D.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[25] An orally bioavailable degrader targeting androgen receptor and the splice variant in castration resistant prostate cancer
Hung, Chiu-Lien
Wang, Ling-Yu
Fu, Chih-Wei
Hsu, Hung-Chih
Kung, Hsin-Jien
CANCER RESEARCH, 2023, 83 (08)
[26] Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug
Lee, BoRa
Kim, Dae Gyu
Lee, Aram
Kim, Young Mi
Cui, Lianji
Kim, Sunghoon
Choi, Inhee
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2023, 38 (01) : 51 - 66
[27] Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer
Hung, Chiu-Lien
Liu, Hao-Hsuan
Fu, Chih-Wei
Yeh, Hsun-Hao
Hu, Tsan-Lin
Kuo, Zong-Keng
Lin, Yu-Chin
Jhang, Mei-Ru
Hwang, Chrong-Shiong
Hsu, Hung-Chih
Kung, Hsing-Jien
Wang, Ling-Yu
EBIOMEDICINE, 2023, 90
[28] The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer
Li, Liuxun
Xu, Jiangli
CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (02): : 352 - 363
[29] The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer
Liuxun Li
Jiangli Xu
Clinical and Translational Oncology, 2023, 25 : 352 - 363
[30] Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer
Bagal, Sharan K.
Astles, Peter C.
Diene, Coura
Argyrou, Argyrides
Crafter, Claire
Cassar, Doyle J.
Fallan, Charlene
Hock, Andreas
Jones, Thomas
Moreau, Kevin
Lamont, Gillian M.
Lamont, Scott
Michaloglou, Chrysiis
Packer, Martin J.
Pike, Andy
Ramos-Montoya, Antonio
Scott, James S.
Shaw, Joseph
Shologu, Ziyanda
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (14) : 11732 - 11750

← 1 2 3 4 5 →